Microsatellite instability and adjuvant fluorouracil chemotherapy: A mismatch?

Journal of Clinical Oncology

Volumn 28, Issue 20, 2010, Pages 3207-3210

  Ng, Kimmie ^a   Schrag, Deborah ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CELECOXIB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; METHOTREXATE; MISMATCH REPAIR PROTEIN; OXALIPLATIN; PLACEBO; PROTEIN BAX; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; RALTITREXED; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; ANTINEOPLASTIC ANTIMETABOLITE;

CANCER ADJUVANT THERAPY; COLORECTAL CANCER; DISEASE FREE SURVIVAL; EDITORIAL; GENE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOSITY LOSS; HUMAN; METASTASIS; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; ADJUVANT CHEMOTHERAPY; COLORECTAL TUMOR; DRUG RESISTANCE; GENETICS; NOTE; RANDOMIZED CONTROLLED TRIAL;

ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; MICROSATELLITE INSTABILITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77954710907     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.9314     Document Type: Editorial

References (42)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 59:225-249, 2009
2. Ionov Y, Peinado MA, Malkhosyan S, et al: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363:558-561, 1993 (Pubitemid 23186645)
3. Parsons R, Myeroff LL, Liu B, et al: Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res 55:5548-5550, 1995
4. Rampino N, Yamamoto H, Ionov Y, et al: Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275:967-969, 1997 (Pubitemid 27087710)
5. Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal-tumor development. N Engl J Med 319:525-532, 1988
6. Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. Science 260:816-819, 1993 (Pubitemid 23167612)
7. Lothe RA, Peltomäaki P, Meling GI, et al: Genomic instability in colorectal cancer: Relationship to clinicopathological variables and family history. Cancer Res 53:5849-5852, 1993 (Pubitemid 24006146)
8. Kim H, Jen J, Vogelstein B, et al: Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 145:148-156, 1994 (Pubitemid 24217493)
9. Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247-257, 2003 (Pubitemid 36859476)
10. Arnold CN, Goel A, Boland CR: Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 106:66-73, 2003 (Pubitemid 36750389)
11. Tajima A, Hess MT, Cabrera BL, et al: The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: Implications for chemosensitivity and resistance. Gastroenterology 127:1678-1684, 2004 (Pubitemid 39575846)
12. Sargent DJ, Marsoni S, Monges G, et al: Defective mismatch repair as a predictive marker for lack of efficacy of 5-fu-based adjuvant therapy in colon cancer. J Clin Oncol 28:3219-3227, 2010
13. Clark GM, Zborowski DM, Culbertson JL, et al: Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib. J Thorac Oncol 1:837-846, 2006 (Pubitemid 47181390)
14. André T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004 (Pubitemid 38702845)
15. André T, Boni C, Navarro M, et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109-3116, 2009
16. Capdevila J, Elez E, Peralta S, et al: Oxaliplatin-based chemotherapy in the management of colorectal cancer. Expert Rev Anticancer Ther 8:1223-1236, 2008
17. Rothenberg ML, Oza AM, Bigelow RH, et al: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 21:2059-2069, 2003 (Pubitemid 46606353)
18. des Guetz G, Mariani P, Cucherousset J, et al: Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer. Anticancer Res 27:2715-2719, 2007
19. Kim ST, Lee J, Park SH, et al: Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol [epub ahead of print on December 24, 2009]
20. Kim ST, Lee J, Park SH, et al: The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer. Med Oncol [epub ahead of print on December 1, 2009]
21. Zaanan A, Cuilliere-Dartigues P, Guilloux A, et al: Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol 21:772-780, 2010
22. Saltz LB, Niedzwiecki D, Hollis D, et al: Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803. J Clin Oncol 25:3456-3461, 2007 (Pubitemid 47310883)
23. Bertagnolli MM, Niedzwiecki D, Compton CC, et al: Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 27:1814-1821, 2009
24. Marra G, Boland CR: Hereditary nonpolyposis colorectal cancer: The syndrome, the genes, and historical perspectives. J Natl Cancer Inst 87:1114-1125, 1995
25. Veigl ML, Kasturi L, Olechnowicz J, et al: Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A 95:8698-8702, 1998 (Pubitemid 28350551)
26. Cunningham JM, Christensen ER, Tester DJ, et al: Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 58:3455-3460, 1998 (Pubitemid 28371090)
27. Rajagopalan H, Bardelli A, Lengauer C, et al: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418:934, 2002 (Pubitemid 34976022)
28. Deng G, Bell I, Crawley S, et al: BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 10:191-195, 2004 (Pubitemid 38114179)
29. Shaukat A, Arain M, Thaygarajan B, et al: Is BRAF mutation associated with interval colorectal cancers? Dig Dis Sci [epub ahead of print on March 19, 2010]
30. Roth AD, Tejpar S, Delorenzi M, et al: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial J Clin Oncol 28:466-474, 2010
31. Di Nicolantonio F, Martini M, Molinari F, et al: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705-5712, 2008
32. Hewish M, Lord CJ, Martin SA, et al: Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol 7:197-208, 2010
33. Bécouarn Y, Gamelin E, Coudert B, et al: Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. J Clin Oncol 19:4195-4201, 2001 (Pubitemid 33081636)
34. Schalhorn A, Ludwig F, Quietzsch D, et al: Phase III Trial of Irinotecan Plus Oxalipatin (IROX) Versus Irinotecan Plus 5-FU/Folinic Acid (FOLFIRI) as First-Line Treatment of Metastatic Colorectal Cancer (CRC): The FIRE-Trial. J Clin Oncol 23:250s, 2005 (abstr 3516)
35. Haller DG, Rothenberg ML, Wong AO, et al: Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol 26:4544-4550, 2008
36. Meyers M, Wagner MW, Mazurek A, et al: DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. J Biol Chem 280: 5516-5526, 2005 (Pubitemid 40280029)
37. Lord CJ, Ashworth A: Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 8:363-369, 2008
38. Vilar Sanchez E, Chow A, Raskin L, et al: Preclinical testing of the PARP inhibitor ABT-888 in microsatellite instable colorectal cancer. J Clin Oncol 27:564s, 2009 (abstr 11028)
39. Koopman M, Kortman GA, Mekenkamp L, et al: Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 100:266-273, 2009
40. De Roock W, Piessevaux H, De Schutter J, et al: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19:508-515, 2008 (Pubitemid 351325672)
41. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
42. Van Cutsem E, Lang I, D'haens G, et al: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 26:52, 2008 (abstr 2)